ArticleHuman vaccines & immunotherapeutics2013
Therapeutic vaccines: the ultimate personalized therapy?
Article in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.Oncotarget · 2016Trial
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Cancer immunology research · 2014Trial
- Review
- MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.BMC cancer · 2020Article
- Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.Journal of the National Cancer Institute · 2020Review
- Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B.Vaccines · 2020Review
- Article
- Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Polyfunctional response by ImmTAC (IMCgp100) redirected CD8Immunology · 2017Article
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.Journal of the National Cancer Institute · 2017Review
- Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Human vaccines & immunotherapeutics · 2016Review
- Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.Oncoimmunology · 2016Review
- Opportunities in immunotherapy of ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Review
- Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.Immunology letters · 2015Article
- Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.Therapeutic advances in vaccines · 2014Review
- Therapeutic cancer vaccines.Advances in cancer research · 2014Review
- Adding fuel to the fire: immunogenic intensification.Human vaccines & immunotherapeutics · 2014Review
- Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.Cancer immunology, immunotherapy : CII · 2013Article
- Dramatic and prolonged PSA response after retreatment with a PSA vaccine.Clinical genitourinary cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Personalized therapy is directed at obtaining maximal therapeutic effect on diseased tissue with minimal off-target side effects. Many classes of therapeutics have attempted to reach this ideal, only to fall well short. Therapeutic vaccines represent a novel class of therapies that can induce a dynamic immune response that, in theory, can continue to adapt and expand following initiation of vaccination. This adaptability, through epitope spreading or antigen cascade, can continuously refine a therapeutic immune response, making it more relevant to the patient's tumor. This active, dynamic, iterative process can continue long after the vaccine course has been completed. Recent clinical trials have provided further insight into the clinical activity of therapeutic vaccines, and offer guidance on clinical expectations following vaccine. The ongoing active sculpting of the immune response, along with the lack of significant side effects, uniquely positions therapeutic vaccines as perhaps the ultimate in personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.